Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Geron
company
About
Geron Corp. operates as a biopharmaceutical company which discovers and develops therapeutic products for cancer. Imetelstat, a novel,
- 101 - 250
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $125M
- Industries
- Biopharma,Biotechnology,Health Diagnostics,Pharmaceutical
- Founded date
- Aug 28, 1990
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Geron Corp. operates as a biopharmaceutical company which discovers and develops therapeutic products for cancer. Imetelstat, a novel, first-in-class telomerase inhibitor, is a product candidate in clinical development.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$125M
Geron has raised a total of
$125M
in funding over 2 rounds. Their latest funding was raised on
Jun 30, 2022 from a Post-IPO Debt round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 30, 2022 | Post-IPO Debt | $125M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Geron is funded by 1 investors.
Hercules Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Hercules Capital
|
— | Post-IPO Debt |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
